Trial Profile
A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Subjects With Mild or Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Aragon Pharmaceuticals
- 20 Aug 2019 Pooled analysis population pharmacokinetic results of Apalutamide from seven clinical trials were published in the Clinical Pharmacokinetics.
- 21 Apr 2017 Status changed from recruiting to completed.
- 08 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.